AI drug discovery is mostly just a fancy way of saying we're
The Gap Between In Silico and In Vivo
Most of these "breakthroughs" happen in silico—which is just a pretentious way of saying "on a computer." An AI agent can screen ten million compounds in a weekend and tell you that Molecule X has a 99% binding affinity for a specific target. Great. Then it hits a real human cell and turns out to be toxic or simply ignored by the body.
If you're looking for a practical tutorial on why these models fail, look at the data. We are training massive models on "positive" data (what worked), but the "negative" data (why things failed) is often locked away in some pharmaceutical company's vault because they don't want to admit they wasted $100 million on a dud. You can't build a robust AI workflow if you're only feeding it the highlight reel.
Where the Actual Wins Are Happening
It's not all hype, though. There are a few areas where a deep dive actually shows progress:
- Target Identification: This is where AI actually shines. Instead of a scientist spending five years reading papers to find a protein to target, an LLM can synthesize that literature in seconds.
- De Novo Design: We're getting better at creating molecules from scratch rather than just searching existing libraries.
- Protein Folding: AlphaFold changed the game, but knowing the shape of a protein isn't the same as knowing how to drug it.
The "Black Box" Problem in Bio
The biggest headache is the lack of interpretability. When a prompt engineering expert tweaks a marketing bot and it starts talking like a pirate, no one dies. When an AI-designed molecule causes an unexpected cytokine storm in a patient, "the model said it would work" isn't a valid medical defense. We need more "glass box" models where we can actually see the causal chain of why a specific molecular structure was chosen.
For anyone trying to build a real-world deployment of these tools, stop obsessing over the model size and start obsessing over the assay quality. A small model trained on pristine, high-fidelity biological data will beat a trillion-parameter monster trained on noisy, public datasets every single time. We don't need "bigger" AI in drug discovery; we need "smarter" data.